Title:
PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS AND METHODS OF THEIR USE
Document Type and Number:
WIPO Patent Application WO/2012/065057
Kind Code:
A3
Abstract:
The invention relates to methods, combinations, and formulations of a compound of Formula I, particularly Compound A.
Inventors:
AFTAB DANA T (US)
DECILLIS ARTHUR (US)
DECILLIS ARTHUR (US)
Application Number:
PCT/US2011/060361
Publication Date:
November 22, 2012
Filing Date:
November 11, 2011
Export Citation:
Assignee:
EXELIXIS INC (US)
AFTAB DANA T (US)
DECILLIS ARTHUR (US)
AFTAB DANA T (US)
DECILLIS ARTHUR (US)
International Classes:
A61K31/498; A61K45/06; A61P35/00; A61P35/02
Domestic Patent References:
WO2008021389A2 | 2008-02-21 | |||
WO2009017838A2 | 2009-02-05 |
Other References:
Y. WU ET AL: "FOXO1A Is a Target for HER2-Overexpressing Breast Tumors", CANCER RESEARCH, vol. 70, no. 13, 15 June 2010 (2010-06-15), pages 5475 - 5485, XP055020903, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-10-0176
T. W. MILLER ET AL: "Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells", CLINICAL CANCER RESEARCH, vol. 15, no. 23, 1 December 2009 (2009-12-01), pages 7266 - 7276, XP055020913, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-1665
HAN L ET AL: "Inactivation of PI3K/AKT signaling inhibits glioma cell growth through modulation of beta-catenin-mediated transcription", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1366, 1 October 2010 (2010-10-01), pages 9 - 17, XP027527870, ISSN: 0006-8993, [retrieved on 20101001]
PIXU LIU ET AL: "Targeting the phosphoinositide 3-kinase pathway in cancer", NATURE REVIEWS DRUG DISCOVERY, vol. 8, no. 8, 1 August 2009 (2009-08-01), pages 627 - 644, XP055020926, ISSN: 1474-1776, DOI: 10.1038/nrd2926
DATABASE BIOSIS, [online] 20 November 2009 (2009-11-20), WALSH KATHERINE J ET AL: "PI3K Inhibitors Inhibit Lymphoma Growth by Downregulation of MYC-Dependent Proliferation", XP002666170, retrieved from BIOSIS Database accession no. PREV201000352691
FDA: "Summary of Color Additives for Use in the United States in Foods, Drugs, Cosmetics, and Medical Devices", 22 March 2007 (2007-03-22), XP002675594, Retrieved from the Internet [retrieved on 20120302]
T. W. MILLER ET AL: "Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells", CLINICAL CANCER RESEARCH, vol. 15, no. 23, 1 December 2009 (2009-12-01), pages 7266 - 7276, XP055020913, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-1665
HAN L ET AL: "Inactivation of PI3K/AKT signaling inhibits glioma cell growth through modulation of beta-catenin-mediated transcription", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1366, 1 October 2010 (2010-10-01), pages 9 - 17, XP027527870, ISSN: 0006-8993, [retrieved on 20101001]
PIXU LIU ET AL: "Targeting the phosphoinositide 3-kinase pathway in cancer", NATURE REVIEWS DRUG DISCOVERY, vol. 8, no. 8, 1 August 2009 (2009-08-01), pages 627 - 644, XP055020926, ISSN: 1474-1776, DOI: 10.1038/nrd2926
DATABASE BIOSIS, [online] 20 November 2009 (2009-11-20), WALSH KATHERINE J ET AL: "PI3K Inhibitors Inhibit Lymphoma Growth by Downregulation of MYC-Dependent Proliferation", XP002666170, retrieved from BIOSIS Database accession no. PREV201000352691
FDA: "Summary of Color Additives for Use in the United States in Foods, Drugs, Cosmetics, and Medical Devices", 22 March 2007 (2007-03-22), XP002675594, Retrieved from the Internet
Attorney, Agent or Firm:
BERVEN, Heidi, M. (Millerschwartz And Cohn, LLP,350 East Michigan Avenue, Suite 30, Kalamazoo MI, US)
Download PDF:
Previous Patent: DIRECT LASER MODULATION
Next Patent: REMOTE CENTER OF MOTION ROBOT FOR MEDICAL IMAGE SCANNING AND IMAGE-GUIDED TARGETING
Next Patent: REMOTE CENTER OF MOTION ROBOT FOR MEDICAL IMAGE SCANNING AND IMAGE-GUIDED TARGETING